All News

Severe COVID-19 was rare in patients with multiple sclerosis even when vaccine responses were impaired.

Secukinumab becomes the only IL-17A inhibitor approved for this population and the first new mechanism in the indication in nearly a decade.

Phase 3 data show lebrikizumab improves skin clearance and itch in children with moderate to severe atopic dermatitis, supporting potential pediatric label expansion.

Vutrisiran kept a favorable safety profile in patients with transthyretin amyloidosis treated for up to 58 months, with AE rates comparable to placebo and no new safety concerns.

Legislation that passed the Senate will introduce reform in how pharmacy benefit managers are addressed by CMS starting in 2028.

Galleri trial data show liquid biopsy multicancer early detection tests may cut stage IV diagnoses, despite the missed primary end point.

Reproductive health conditions raise child desire but lower pregnancy intentions, spotlighting infertility gaps in women’s health and urging proactive counseling and coverage reform.

The website officially launched on February 5, introducing a key part of the Trump administration’s health care plan.

New studies link abortion bans to higher births and WIC demand and spotlight care-access gaps, cancer disparities, and value-based reforms shaping 2026.

GPT-4o reliably scored alopecia areata severity from scalp images, showing strong concordance with experienced dermatology providers without prior AI training.

Deupirfenidone received orphan drug designation from the FDA and European Commission for idiopathic pulmonary fibrosis treatment.

The findings bolster the case for using Bruton tyrosine kinase inhibitors in the treatment of Richter syndrome.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

Experts examine MFN pricing, the Great Healthcare Plan, ACA subsidies, PBM reform, and CMS talks in 2026.

Experts discussed how systemic changes need to be made to help improve preventive care access, which in turn can improve outcomes.

Lindsey Dawson, MA, speaks about how budget decisions regarding ADAPs in Florida could affect patients with HIV should these decisions be made permanent.

Sivelestat significantly reduced the incidence of postoperative ARDS, lowered 90-day mortality, and suppressed inflammatory biomarkers linked to lung injury.

Resmetirom shows sustained quality-of-life gains in MASH and cirrhosis, easing abdominal symptoms and disease worry as liver fat drops.

Risk-based mammography tailors screening to breast cancer risk, reducing false positives and preventing more deaths than age-based screening.

Cost barriers push Latino adults to delay care, raising emergency department visits.

Michael Bernstein, MD, discusses how AI-assisted radiology workflows affect liability, automation bias, and patient safety in diagnostic imaging.

Accountable care experts say the future of value in Medicare will rely on scaling up innovation, emphasizing downstream prevention, and staying alert to waste.

Peter Staley at CROI 2026 on defending 45 years of HIV progress: how clinicians, payers, and advocates can resist—quietly or publicly—and why it matters.

MajesTEC-9 supports moving teclistamab earlier in myeloma treatment, with robust PFS and OS gains over standard care in the second-line setting, notes Roberto Mina, MD.

Racial and geographic CRC disparities described in a recent report highlight the need for urgent research and prevention efforts nationwide.

Patients identified as having a Janus kinase inhibitor responder profile were much more likely to respond positively to the class of atopic dermatitis therapies.

A new nasal spray for patients with chronic spontaneous urticaria could eliminate the need for injectable epinephrine.